Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 5/20 | 0.59 |
| ▸ | RAD52 | P43351 | 4/20 | 0.59 |
| ▸ | KDM1A | O60341 | 8/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | TTR | P02766 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4289539 | 0.78 | MAPT (0.46) | POLBKMT2AMAPTKDM4EGLA | |
| SCHEMBL4289049 | 0.77 | CYP19A1 (0.55) | — | |
| SCHEMBL4292921 | 0.75 | HDAC3 (0.57) | POLBRAD52KDM1AKMT2AGFER | |
| SCHEMBL4293634 | 0.75 | HDAC3 (0.61) | POLBRAD52KDM1AKMT2AGFER | |
| SCHEMBL9603150 | 0.69 | HDAC3 (0.67) | POLBRAD52KDM1AKMT2AGFER | |
| SCHEMBL8005214 | 0.69 | KDM1A (0.69) | POLBRAD52KDM1AKMT2AGFER | |
| SCHEMBL10313324 | 0.69 | KDM1A (0.50) | POLBRAD52KDM1AKMT2AGFER | |
| SCHEMBL13889178 | 0.69 | KDM1A (1.00) | POLBRAD52KDM1AKMT2AGFER | |
| SCHEMBL1865096 | 0.67 | POLB (0.64) | POLBRAD52KMT2AACHEAPP | |
| SCHEMBL9594504 | 0.67 | KDM1A (0.69) | POLBRAD52KDM1AKMT2AGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275664-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | PROGEN PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7279502-B2 | Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CELLGATE, INC. (US) | 2007-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275664-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CTSB, CTSL, CTSV | POLB 229/4885RAD52 1451/4885KDM1A 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.